James A. Boiani, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Reuters, in “US Could Take Action Including Fines Against Hims After Brief Wegovy Copy Launch,” by Leah Douglas and Amina Niasse.
Following is an excerpt:
The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, attorneys and other experts told Reuters.
Hims and Hers Health (HIMS.N) last week said it would offer a much cheaper $49 version of Novo Nordisk's (NOVOb.CO) Wegovy weight-loss pill, before backing off the plan after the Food and Drug Administration said it would take steps against the company. …
Because Hims said on Saturday that it will no longer offer the compounded weight-loss pill, the Department of Justice could decide not to take action against the company after all, said James Boiani, an attorney at Epstein, Becker & Green, P.C.
"If Hims has already stepped back and is saying we’re not going to do this, it’s not clear there’s a case or controversy here," he said.
The administration could turn its attention to Hims' compounded injectable weight-loss drugs, which are also based on the active ingredient semaglutide found in Novo's Wegovy.
